3,300,000 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC bought a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,300,000 shares of the company’s stock, valued at approximately $32,769,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of LXEO. AQR Capital Management LLC lifted its stake in Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock valued at $175,000 after acquiring an additional 39,627 shares during the period. Millennium Management LLC increased its stake in shares of Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after acquiring an additional 929,538 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Lexeo Therapeutics during the first quarter worth $85,000. Rhumbline Advisers raised its holdings in shares of Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after purchasing an additional 4,995 shares during the last quarter. Finally, Cerity Partners LLC acquired a new position in Lexeo Therapeutics during the second quarter valued at $50,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Insider Activity at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 55,000 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the sale, the chief executive officer owned 340,106 shares of the company’s stock, valued at $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 59,644 shares of company stock worth $336,462 over the last three months. 2.00% of the stock is owned by insiders.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $4.93 on Friday. The company’s fifty day moving average price is $5.40 and its 200 day moving average price is $6.90. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The stock has a market capitalization of $387.10 million, a P/E ratio of -3.40 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.23 EPS for the current year.

Analyst Ratings Changes

LXEO has been the topic of several analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.14.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.